Posted on

Flexibilisation of COVID-19 measures

Following the evolution of the incidence of the pandemic in Spain and the gradual reduction of COVID-19 infections, ROVI will recover face-to-face assistance for employees in NON-industrial offices as of 7 March.

  • The return to the offices will be staggered and will start with a 50% attendance rate, that is five out of every ten working days will be spent in the office, with employees having to guarantee attendance at least one day each week.
  • We will withdraw temperature-based access control at our sites.
  • It will continue to be compulsory to wear a face mask indoors except when eating at the workplace.
  • We continue to recommend regular ventilation of work areas and will maintain daily cleaning of workstations with virucides.

All these measures will be reviewed according to the evolution of the indications of the health authorities applying to the workplaces and the evolution of the epidemiological situation.

We would like to remind you that, as of 7 March, any ROVI employee who:

  • Shows symptoms compatible with COVID-19 infection or has tested positive in a self-diagnosis test should contact the following telephone number of the Community of Madrid 900 102 112 or their health centres if they are in another community and maintain self-isolation for 7 days. You should also write to notificacionescovid19@rovi.es to notify them. If you receive medical leave, you should manage it directly with HR.
  • If you have been a close contact of a confirmed positive, you should write to notificacionescovid19@rovi.es for individual assessment.

Posted on

ROVI achieved operating revenue growth of 54% in 2021

ROVI reports the financial results obtained in 2021, a historic year for the group in terms of the figures achieved and the capabilities it demonstrated to adapt to the needs of the pandemic.

ROVI achieved operating revenue growth of 54% compared to 2020. This result was mainly driven by the strength of the contract manufacturing organization business, which grew by 189% and by the specialty pharmaceutical business, where sales rose 17%.

Net profit totalled 153.1 million, 151% up on the preceding year. EBITDA rose by 115% to 202.9 million euros in 2021, reflecting a 8.8 percentage point increase in the EBITDA margin, which rose to 31.3% in 2021 from 22.4% in 2020.

Sales of prescription-based pharmaceutical products rose 17% to 347.2 million euros in 2021.

Juan López-Belmonte, Chairman and Chief Executive Officer of ROVI said that “the 2021 results are historic for ROVI and demonstrate our company’s ability to continuously adapt”.

Posted on

Moderna and ROVI expand long-term collaboration for the next ten years

Moderna and Laboratorios Farmacéuticos Rovi today announced a long-term collaboration to increase capacities for the compounding, aseptic filling, inspection, labeling, and packaging of ROVI’s facilities located in Madrid, San Sebastián de los Reyes and Alcalá de Henares.

This new agreement, which has a term of ten years, includes a series of investments expected to allow the manufacturing capacity to increase across ROVI’s facilities in Madrid, Spain. In addition to producing Moderna’s COVID-19 vaccine, ROVI’s platform could also be utilized to service future Moderna mRNA vaccine candidates.

“ROVI has been a pivotal partner in supporting the manufacturing of our COVID-19 mRNA vaccine for countries outside of the U.S., and this long-term agreement expands our partnership and allows for further scale-up for future mRNA medicines,” said Juan Andrés, Moderna’s Chief Technical Operations and Quality Officer.

Mr. Juan López-Belmonte Encina, ROVI’s Chairman and Chief Executive Officer, said: “We are delighted to expand our collaboration with Moderna and become a long-term manufacturing partner. At ROVI we are working to contribute all our experience as a high-technological-value contract manufacturer of injectables to the solution of this pandemic and we are confident of our ability to take part in the manufacturing of new mRNA candidates in the future.”

Moderna and ROVI are expected to finalize details of this agreement in the first quarter of 2022.

Posted on

ROVI receives the European Commission’s approval of Okedi® as a treatment for schizophrenia

Today, ROVI has announced that the European Commission has authorised the marketing of Okedi® (Risperidone ISM®) for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone, since, as of the first injection, it provides immediate and sustained plasmatic drug levels and does not require loading doses or supplementation with oral risperidone.

This approval is based on the positive results of the pivotal PRISMA-3 study on the efficacy and safety of Risperidone ISM® in schizophrenia patients.

“We are very excited about the European Commission’s approval of Risperidone ISM® because we think our medicine will be able to contribute to the clinical management of schizophrenia patients. Likewise, we hope to launch the product in Europe in the second quarter of 2022”, commented Juan López-Belmonte Encina, ROVI’s Chairman and Chief Executive Officer.

Regarding other territories, ROVI filed the application for marketing authorisation of Risperidone ISM® with the United State Health authorities, the U.S. Food and Drug Administration (“FDA”) on 24 November, 2020 and the dossier is currently being reviewed by the FDA. Recently, the FDA informed ROVI of a delay in making a decision on the grant of said marketing authorisation.

Posted on

Stay safe from Phishing

Last week we launched a simulated phishing attack, with the subject line: “Urgent – Your email account is full”. The objective was to measure the level of awareness and reaction we have in the organisation to this type of attack.

This exercise has shown that, although many of you have applied what you learnt in the cybersecurity campaigns conducted in 2021, others did not identify the danger signs and fell for the scam, allowing your credentials, username and password to be stolen; this is very serious for the security of our company.

During this year 2022 we will continue with a new campaign to reinforce and raise awareness of everything related to cybersecurity. Those of you who have fallen into the deception of this simulation will receive a special mandatory training action that will be communicated to you individually.

We would like to take this opportunity to congratulate those who have applied what they have learned and remind you of the keys to phishing, the most important of which is to know what can be asked of you and in what way, to be surprised by what is not normal and to ask if you have any doubts.